Statement of Principles concerning acute myeloid leukaemia (Reasonable Hypothesis) (No. 21 of 2024)

The instrument revolves around a small set of legal-medical concepts that determine how AML claims are assessed under the VEA/MRCA framework. Core concepts are: (1) the definition of the covered disease; (2) enumerated “causal” factors and their numeric or temporal thresholds; (3) the concept of "reasonable hypothesis"; (4) the relation of a factor to relevant service; and (5) cross-application with other Statements of Principles.

1. Disease definition (s7). Acute myeloid leukaemia is defined clinically and inclusively as a malignant myeloid-lineage neoplasm characterised by excess myeloblasts, and the instrument lists specific AML subtypes that are within scope (s7(2)(a)-(b)). It expressly excludes chronic myeloid leukaemia and myelodysplastic syndrome (s7(2)(c)). The instrument also treats death from AML as including death from a terminal event or condition contributed to by AML (s7(3)), with "terminal event" defined in the Schedule.

2. Enumerated factors (s9). Section 9 lists 18 discrete factors; the existence of at least one, properly connected to relevant service, is the minimum required to raise a reasonable hypothesis. These factors include personal behaviours (smoking quantified in pack-years and timing at s9(1) and Schedule definitions), antecedent haematological disorders (s9(2)-(3)), prior treatments and specific drugs with long latency windows (s9(4) and associated examples in notes), ionising radiation thresholds expressed as cumulative equivalent dose (s9(5) and Schedule definition), ablative radioactive treatments (s9(6)-(7)), specific chemical exposures with duration and timing thresholds (benzene at s9(8)-(9), styrene at s9(16)-(17), formaldehyde at s9(13)), obesity (s9(10)), organ or haematopoietic stem cell transplantation (s9(11)), HIV infection (s9(12)), specified autoimmune diseases (s9(14)), pesticide exposures with cumulative hours limits (s9(15)), and inability to obtain appropriate clinical management (s9(18)).

3. Quantitative thresholds and temporal windows. Many factors are expressed as numeric thresholds and latency windows. Examples: smoking requires at least 10 pack-years commencing at least five years before clinical onset, with cessation windows (s9(1) and Schedule definitions); benzene requires at least 1,250 cumulative hours within a continuous five-year period with first exposure at least two years before onset (s9(8)), or exposure exceeding 5 ppm-years (s9(9)); styrene exposure thresholds are specified as cumulative hours (2,500 hours in five years) and a ppm-years threshold greater than 10 ppm-years (s9(16)-(17)); formaldehyde requires 5,000 cumulative hours within a continuous 10-year period with the first exposure at least five years before onset (s9(13) and Schedule definition for inhaling formaldehyde). Ionising radiation is set at a cumulative equivalent dose of at least 0.01 sievert to bone marrow at least one year before clinical onset (s9(5)).

4. Measurement concepts in the Schedule. The Schedule defines technical measurement concepts used to operationalise thresholds: 8-hour time-weighted averages, ppm-years, one pack-year, BMI and obesity, inhalation thresholds for formaldehyde and styrene, cumulative equivalent dose with reference to an ARPANSA guide, and what it means to be “exposed to benzene as specified” (Schedule 1). The ARPANSA guide is explicitly referenced as the methodology for dose reconstruction (Schedule definition of cumulative equivalent dose).

5. Relationship to service and other SOPs. Section 10 requires the factor to be related to the person’s relevant service (s10(1)). Section 11 prescribes that where a factor refers to an injury or disease covered by another Statement of Principles, the factors in that other Statement apply as in force from time to time (s11). This establishes a hierarchy and interdependence between Statements.

Together these concepts create an evidence architecture: a claimant must identify an enumerated factor, quantify it per the Schedule, and show a link to relevant service. Decision-makers assess whether, on those facts, a reasonable hypothesis exists that AML is connected to the person’s service.

Primary affected parties

• Veterans, members of Peacekeeping Forces, and members of the Forces covered by the VEA or the MRCA who make claims under s120A of the VEA or s338 of the MRCA (s5). These persons are claimants who allege AML or death from AML connected to relevant service.

• The Department or agency that adjudicates VEA/MRCA claims, which must apply this Statement when assessing whether a reasonable hypothesis has been raised (the instrument is made under s196B(2) of the VEA; s3 and s5).

• Medical and occupational experts engaged to give opinions on causal connection, latency, and exposure quantification, because the Statement prescribes specific medical definitions and exposure threshold metrics (s7, s9, Schedule).

Secondary affected parties

• Treating clinicians and hospitals that must supply medical records documenting diagnosis, clinical onset, antecedent haematologic disorders, transplant history, treatments received and dates (s7, s9, Schedule).

• Employers and record-keepers (including Defence records) who hold occupational exposure data such as air monitoring results, task logs, industrial hygiene reports, or maintenance logs that enable calculation of cumulative hours, ppm-years, or 8-hour TWA exposures (s9(8)-(9), s9(13), s9(16)-(17), Schedule).

• Laboratories and diagnostic services that provide pathology reports establishing AML subtype and clinical onset date (s7(2), s7(3)).

Who bears the costs

• Claimants bear the practical cost of assembling documentary evidence to meet the thresholds , medical records, occupational exposure data, employment records, service records , and may need specialists (hematologists, occupational hygienists) or dose reconstruction experts. For ionising radiation dose reconstruction the instrument points to an ARPANSA methodology (Schedule), implying technical cost and reliance on expert assessments.

• The administering agency bears the administrative cost of assessing claims using the Statement, which may include commissioning dose reconstructions or expert opinions to apply the ARPANSA methodology and interpret exposure thresholds.

Who decides

• The RMA determined the medical criteria (s3 and s8). Application of those criteria to individual claims will be decided under the VEA/MRCA decision-making processes referenced by s5. The Statement does not itself produce determinations in individual cases; it supplies the medical framework decision-makers must apply.

Potential distributional effects

• Claimants with well-documented exposures (e.g., clear Defence records of benzene or radiation exposure, or medical records showing prior MDS or prior treatments with listed drugs) will be advantaged because the Statement sets clear thresholds and timing windows. Conversely, claimants lacking service or occupational records that can be used to quantify exposures will face evidential disadvantage.

• Certain factors (e.g. smoking, obesity, autoimmune disease) are personal health attributes; inclusion of these as qualifying factors means individuals with documented personal health risk factors may satisfy the minimum threshold in s9. This produces concentrated evidential benefit for claimants with those histories but also raises questions about the interaction with service-related exposure proof, because s10 requires the factor to be related to the person’s relevant service.

Duties

• Duty to link: A person seeking to rely on any factor in s9 must show that the factor is related to the person’s relevant service (s10(1)). The instrument does not specify the procedural method for proving that link; it sets a substantive requirement for decision-makers.

• Duty to meet defined thresholds: Each factor in s9 is presented with specific numeric, temporal or categorical requirements. The onus is on the claimant to marshal evidence that the factual prerequisites are met, for example showing pack-year calculations per the Schedule for smoking (s9(1) and Schedule), or demonstrating cumulative hours of benzene exposure (s9(8)).

• Duty to apply other SOPs where applicable: If a factor references an injury or disease for which another Statement of Principles exists, the decision-maker must apply the factors in that other Statement as in force from time to time (s11). This imposes a duty on decision-makers to consult and apply relevant Statements rather than treating factors in isolation.

Rights

• Right to have a claim assessed using this Statement: For a claim under s120A VEA or s338 MRCA, the Statement is the prescribed medical instrument. Claimants have the right to have adjudicators assess whether the statutory threshold of a reasonable hypothesis is raised by the factors specified (s5, s8, s9).

• Right to rely on death proximate causes: The Statement explicitly includes death from AML that was contributed to by the person’s AML, capturing terminal events listed in the Schedule (s7(3), Schedule terminal event). This gives claimants the right to have mortality cases considered where AML materially contributed to a listed terminal event.

What decision-makers are empowered to do

• Use ARPANSA methodology for dose reconstruction: The Schedule ties cumulative equivalent dose calculations to the ARPANSA guide in force on 2 August 2017 (Schedule definition of cumulative equivalent dose). Decision-makers are empowered to rely on that methodology to calculate ionising radiation doses.

• Treat overlapping diseases according to other SOPs: Where a s9 factor is itself an injury/disease subject to another Statement, decision-makers must apply that other Statement’s factors (s11). This creates an interlocking framework for adjudication across related diseases.

What the Statement does not do

• The instrument does not specify procedural steps (e.g. evidence burden, timeframes, appeals). Those aspects remain governed by the VEA and MRCA processes referenced in s5.

• It does not prescribe penalties or enforceable criminal sanctions. It also does not itself award compensation; it supplies medical criteria for decision-makers to apply.

The Statement is a medical-diagnostic instrument, not an enforcement or penal statute. It contains no express criminal penalties, civil fines, or enforcement mechanisms. Its operative force is to guide decision-makers under the VEA and MRCA when determining whether a reasonable hypothesis exists connecting AML to relevant service. The following practical enforcement and adjudicative features arise from the instrument’s text and structure.

Enforcement via administrative decision-making

• Application through VEA/MRCA: The instrument's legal effect depends on administrative decision-making under s120A of the VEA or s338 of the MRCA (s5). Any enforcement, denial, or acceptance of claims occurs through those statutory processes; penalties or sanctions for false claims or misconduct would be governed by those statutes and their procedures, not by this Statement.

• Evidence-based administrative application: The RMA supplies discrete, measurable thresholds and definitions (s9 and Schedule). Administrative enforcement in practice will mean the adjudicating authority (Department or delegate) evaluates documentary and expert evidence against those thresholds. Non-compliance with a threshold is not a penalty but a reason to find the reasonable hypothesis not raised.

No criminal or civil penalty provisions in the instrument

• The Statement does not specify criminal sanctions for misrepresentation of exposures or falsified records. It neither creates nor imposes investigatory powers (search, inspection) or penalty regimes. Any such actions would have to be taken under other laws.

Reliance on expert assessments and third‑party data

• The instrument references technical methodologies (e.g. cumulative equivalent dose calculation per ARPANSA) that will typically require expert assessment to apply. Administratively, the decision-maker may commission or rely on such experts. There is no enforcement power within the instrument to compel third parties to produce occupational monitoring data; compulsion would be via the claims process and associated statutory powers elsewhere.

Compliance oversight and review

• The instrument itself does not set internal oversight or review mechanisms. Judicial or merits review of decisions applying the Statement may be available under the VEA or MRCA frameworks or general administrative law, but the Statement contains no procedural or appeal provisions.

Potential practical enforcement consequences

• For claimants, failure to provide sufficient evidence to meet the thresholds effectively produces refusal of a claim rather than a penalty. For employers/record-keepers, the practical consequence of poor record-keeping is that employees/veterans cannot prove exposure thresholds; again, there's no penalty clause in the Statement.

• Administrative compliance costs may be incurred by the Department in seeking dose reconstructions, industrial hygiene reports and expert opinions to apply the Statement’s technical thresholds. These are implementation costs rather than statutory fines.

In short, the instrument defines what evidence is required to raise a reasonable hypothesis linking AML to service; it does not itself create enforcement sanctions. The administrative application of the Statement within the VEA/MRCA frameworks is the channel by which the Statement’s criteria have practical effect.

This Statement is expressly an instrument made under subsection 196B(2) of the VEA (s3). Its interaction with the wider legal framework is principally through the claims and adjudicative machinery of the VEA and MRCA, and through cross-references to other Statements of Principles.

Interaction with the VEA and MRCA

• Applicability: The instrument applies to claims to which s120A of the VEA or s338 of the MRCA applies (s5). It therefore operates within those statutory regimes; the decision-makers who adjudicate under those provisions will apply this Statement as the medical standard for assessing whether a reasonable hypothesis connects AML to relevant service.

• Threshold standard: The Statement supplies the specific factors that are treated as raising a "reasonable hypothesis" when linked to relevant service. It does not alter the legal test in the VEA/MRCA statutes themselves; rather, it operationalises the medical side of the statutory causation inquiry by enumerating factors (s9) and requiring linkage to relevant service (s10(1)).

Cross-application with other Statements of Principles

• Section 11 provides an interaction rule: if a s9 factor refers to an injury or disease for which another Statement of Principles exists, the factors in that other Statement apply as in force from time to time (s11). This creates a system whereby issues that straddle multiple disease categories are addressed by the separate SOPs for those diseases. For example, s9(2) lists myelodysplastic syndrome as a factor; but s7(2)(c) excludes myelodysplastic syndrome from the AML definition. If there is a separate SOP for myelodysplastic syndrome, that document’s factors will govern how MDS is treated as a related disease in causation enquiries.

Methodological interplay with scientific guidance

• Cumulative equivalent dose reliance on ARPANSA guide: The Schedule defines cumulative equivalent dose with reference to the ARPANSA Guide "as in force on 2 August 2017" (Schedule). This anchors dose reconstruction to a scientific methodology developed under another regulatory regime (ARPANSA), integrating administrative scientific guidance into the VEA framework. The instrument thus imports external technical methodology without reproducing it.

No express conflict resolution clause beyond s11

• Where there is potential overlap between this Statement and other legislation or instruments, s11 directs decision-makers to apply other Statements of Principles when s9 factors reference those diseases. The instrument does not specify a broader conflict-of-laws rule; routine statutory interpretation and the structure of the VEA/MRCA will govern any other interaction.

Implications for procedural and evidentiary rules

• Procedural rules for claims, burden of proof, admissibility of evidence, and review processes remain governed by the VEA, MRCA and associated regulations and administrative law; this Statement does not modify those procedures. It is a substantive medical-direction instrument to be applied within the adjudicative processes of those Acts (s5, s3).

Relations to occupational, environmental and public health law

• The Statement’s exposure thresholds (benzene, styrene, formaldehyde, ionising radiation) mirror industrial hygiene concepts used in occupational health regulation. The instrument does not, however, create obligations under workplace health and safety laws; it simply uses occupational exposure metrics for causation assessment in veterans’ entitlements. Any regulatory obligations or enforcement under workplace safety law are separate.

In sum, the Statement functions as a specialised medical-administrative instrument that integrates scientific definitions and exposure thresholds (some sourced from other technical guidance) into the VEA/MRCA claim assessment process. It interacts with other SOPs via s11 and with external scientific methodology via the Schedule’s ARPANSA reference, but it does not itself change procedural law or create separate enforcement powers.

This instrument records two explicit historical datapoints: the replacing of the 2015 Statement and its own dates of execution and commencement.

• Repeal of previous instrument: Section 4 repeals "The Statement of Principles concerning acute myeloid leukaemia No. 71 of 2015 (Federal Register of Legislation No. F2015L00903)" that was made under subsection 196B(2) of the VEA. The 2024 instrument therefore supersedes the 2015 Statement once it commences (s2 and s4).

• Dates of execution and commencement: The instrument is dated 22 February 2024 (signature of the Chairperson recorded on the instrument). It commences on 26 March 2024 (s2). The Item showing the Common Seal and Chairperson’s name (Professor Terence Campbell AM) documents formal execution.

Internal content changes compared with the repealed instrument

• The instrument itself does not set out a schedule of amendments from the 2015 version or a consolidated comparison. It simply effects repeal and replacement (s4). Any substantive changes (for example, differing exposure thresholds, inclusion/exclusion of subtypes, or new factors) must be determined by comparison with the 2015 instrument; the replacement indicates the RMA has updated its view of the medical-scientific evidence underpinning the Statement (s8).

Reference to external methodological materials

• The Schedule ties calculations for cumulative equivalent dose to the "Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017." This is an external technical document brought into the Statement’s operational framework. Any future update in that guide after 2 August 2017 is not directly incorporated by reference in the Schedule, which fixes the methodology to the version "as in force on 2 August 2017" (Schedule definition). The Schedule also notes examples of circumstances that might lead to ionising radiation exposure.

Future amendment pathways

• The RMA is the statutory body empowered to make Statements under s196B(2) of the VEA (s3). Any future amendment or replacement of this Statement would require exercise of the RMA’s statutory power to determine a new Statement or to vary an existing one. The instrument does not itself prescribe a review schedule.

Practical advice implicit in amendment provisions

• Because the instrument repeals the 2015 Statement and becomes operative on 26 March 2024, claims lodged after commencement will be assessed against the 2024 Statement where the VEA/MRCA provisions require application of the current Statement. Parties handling claims must therefore ensure they apply the 2024 factors and definitions when preparing or adjudicating post‑commencement claims.

The instrument’s amendment history is therefore short and self-contained: it replaces the 2015 Statement with the 2024 Statement and anchors certain technical definitions to a dated ARPANSA guide.

The instrument itself does not record nor reference any judicial decisions or litigation concerning its content. It expressly repeals the earlier 2015 Statement (s4), but no case law or administrative appeals are noted within this document.

What the instrument records

• No litigation is mentioned in the text. There are no citations to judicial review, appellate decisions, or precedential determinations. The document is a Statement of Principles, a medical-administrative instrument intended to guide adjudication under the VEA and MRCA, and documents such as this rarely include litigation histories inside the instrument text.

Implications for practitioners

• Absence of litigation references in the instrument means practitioners must rely on the VEA/MRCA statutory and administrative law frameworks for any procedural or review avenues. If disputes arise about application of the Statement to individual claims, remedies (merits review, administrative review or judicial review) would proceed under the relevant Act and general administrative law principles, not under any procedural apparatus within the Statement.

• Section 11’s cross-reference to other Statements of Principles creates potential for overlapping SOPs and interpretive issues; where such overlap leads to contested factual or legal issues, litigation or merits review may follow. The instrument does not identify any prior judicial interpretation of the factors it lists.

How to check for relevant case law

• The instrument’s repeal of the 2015 Statement does not in itself foreclose challenges to decisions made under that earlier instrument; however, the current Statement’s enactment means future decisions should be assessed using the new factors. Practitioners seeking litigation history relevant to application of AML-related SOPs will need to search external legal databases for decisions applying SOPs for AML, MDS, myeloproliferative neoplasms, ionising radiation exposure, benzene exposure and other listed factors.

Concluding note

• This document contains no litigation record. For any precedent, challenge or review impacting interpretation or application of the Statement, readers must consult VEA/MRCA case files, tribunal decisions, or judicial determinations external to the instrument itself.

The instrument contains several technical and interpretive traps for claimants and decision-makers. These are practical points where misunderstandings or incomplete evidence commonly lead to unsuccessful claims or misapplication of the Statement. Each "gotcha" below is grounded in specific provisions.

1. Disease exclusion vs factor inclusion: myelodysplastic syndrome

• The instrument defines AML and expressly excludes myelodysplastic syndrome from the definition of AML (s7(2)(c)). Yet s9(2)(a) lists myelodysplastic syndrome as a factor that must exist at the time of clinical onset. That is not contradictory within the instrument’s logic: the SOP treats MDS as a separate pre-existing disease that, if present at AML onset, qualifies as an antecedent factor. Practitioners must not conflate an exclusion from the AML definition with the exclusion of MDS as a qualifying antecedent. Where MDS is present, s11 may require applying the MDS Statement of Principles if one exists.

2. Precision of temporal windows and latency

• Many factors include minimum latency or maximum cessation windows (for example, smoking requires commencement at least 5 years before clinical onset; cessation must be within 15 years of onset if smoking has ceased; s9(1)). Radiation requires at least one year between exposure and onset for cumulative equivalent dose (s9(5)). Formaldehyde, styrene and benzene exposures each specify minimum times between first exposure and clinical onset (s9(8), s9(9), s9(13), s9(16)-(17)). Small errors in calculating clinical onset dates or first‑exposure dates can defeat a claim. Practitioners must verify dating carefully and document onset with pathology or medical records (s7(2)-(3)).

3. Quantitative measurement specificity , ppm-years, cumulative hours and 8-hour TWA

• The instrument relies on industrial hygiene metrics: ppm-years, cumulative exposure hours within defined windows, and 8-hour TWA thresholds (Schedule). Evidence must either provide direct measurements or be amenable to reconstruction. Absent contemporaneous air monitoring, claimants will need expert industrial hygiene reconstructions; generic assertions of exposure are unlikely to meet the numeric thresholds.

4. Smoking pack-year calculation specifics

• "One pack-year" is strictly defined as 20 cigarettes per day for one year or equivalent weight of tobacco; equivalences for pipe tobacco, cigars and grams are specified (Schedule). Errors in converting tobacco quantities or in the pack-year arithmetic will affect whether the 10 pack-year threshold in s9(1) is met. The Schedule also offers conversion guidance (7,300 grams as equivalent to 1 pack-year per year if smoked 20/day), which demands careful application.

5. Cumulative equivalent dose anchored to an ARPANSA guide

• The cumulative equivalent dose refers to a specific ARPANSA guide "as in force on 2 August 2017" (Schedule). Practitioners must use that methodology for dose reconstruction, not an ad hoc or different ARPANSA version. Failure to apply the referenced methodology may lead to disputes about the validity of a dose calculation.

6. Factor 9(18) narrow application

• The inability to obtain appropriate clinical management (s9(18)) applies only to material contribution to, or aggravation of, AML where the AML was suffered or contracted before or during (but did not arise out of) relevant service (s10(2)). That is a narrower application than other factors; it cannot be used to bootstrap a claim where AML first arose out of relevant service.

7. Cross-application complexity (s11)

• If a factor points to another disease covered by a separate SOP, decision-makers apply the other SOP's factors "as in force from time to time" (s11). That raises practical issues: which version of the other SOP applies, how to reconcile differing thresholds, and how to sequence medical evidence. Practitioners should identify any related SOPs early (for example, SOPs for MDS or myeloproliferative neoplasms) and assemble evidence to satisfy the applicable SOP(s).

8. Substitution and multiple-factor risks

• The Statement requires at least one factor to exist; it does not require exclusivity or the absence of non-service‑related risk factors. Where multiple factors are present (for example, significant smoking plus occupational benzene exposure), decision-makers must assess whether a reasonable hypothesis exists that links AML to service. Multiple non-service risk factors may complicate causation analysis but do not automatically exclude a finding. Practitioners must present a causal articulation that ties at least one listed factor to relevant service.

9. Measurement thresholds vs real-world exposures

• The instrument’s numeric thresholds (1,250 benzene hours, 5,000 formaldehyde hours, 2,500 styrene hours) may not map neatly to real-world tasks or records. Activities with intermittent exposures or low-level chronic exposures require reconstruction to express exposures in the required cumulative metrics; poor records will likely mean failure to meet the specific numeric thresholds, even where a plausible exposure existed.

10. Death proximate cause framing

• Death from AML includes death from a terminal event contributed to by AML (s7(3)). Practitioners must demonstrate that AML contributed to the terminal event listed in the Schedule (e.g. pneumonia, respiratory failure, cardiac arrest). A death certificate alone may not be sufficient if it lists a terminal event unconnected to AML; linkage should be established in medical records.

These are practical evidence and interpretation pitfalls that will commonly determine outcomes. Addressing them requires precise dates, quantitative exposure measures or reliably documented reconstructions, adherence to the Schedule’s definitions (including the ARPANSA reference), and attention to interaction with other SOPs.

Compliance in this context means preparing a claim or an adjudicative assessment that satisfies the Statement’s substantive requirements so that a "reasonable hypothesis" is raised that AML or death from AML is connected to relevant service. The Statement sets out what evidence and calculations are needed; compliance therefore involves assembling documentation and expert inputs that match those requirements.

1. Establish the clinical diagnosis and clinical onset date (s7)

• Obtain and collate pathology reports, haematology consult notes and hospital records confirming the AML diagnosis and subtype (s7(2)(a)-(b)). Clinical onset date must be documented because many factors require timing relative to the clinical onset (s9 entries regularly refer to "before clinical onset" and minimum latency windows).

• For death claims, obtain cause of death documentation and medical records that show AML contributed to the terminal event (s7(3) and Schedule terminal event list).

2. Identify which s9 factor(s) may apply

• Go through s9 systematically and identify any factors that could apply: smoking history (s9(1)), antecedent haematological disorders (s9(2)-(3)), prior chemotherapeutic agents or specified drugs (s9(4)), radiation exposure (s9(5)-(7)), benzene, styrene, formaldehyde exposures (s9(8)-(9), s9(13), s9(16)-(17)), obesity duration (s9(10)), transplant/infection/autoimmune disease (s9(11)-(14)), pesticide exposure (s9(15)), inability to obtain management (s9(18)).

3. Quantify exposures and durations per Schedule definitions

• For smoking: calculate pack-years per Schedule method (pack-year defined as 20 cigarettes/day for one year; equivalences for grams of tobacco) and document start/stop dates (s9(1) and Schedule). Show smoking commenced at least five years before clinical onset and, if ceased, that cessation was within 15 years of onset.

• For benzene, styrene and formaldehyde: assemble occupational exposure data to calculate cumulative exposure hours within the specified continuous periods and show the date of first exposure relative to clinical onset (s9(8), s9(9), s9(13), s9(16)-(17), Schedule). If contemporaneous monitoring exists, use it. If not, commission an occupational hygienist to reconstruct exposures from job tasks, materials handled, ventilation and similar factors. Ensure reconstructions convert to the Schedule’s 8-hour TWA and ppm-year metrics when required.

• For pesticides: compile work logs, exposure task records and product use histories to document cumulative hours of contact (s9(15)).

• For ionising radiation: commission dose reconstruction using the ARPANSA methodology referenced in the Schedule to calculate cumulative equivalent dose to bone marrow and confirm the dose meets or exceeds 0.01 sievert at least one year before clinical onset (s9(5) and Schedule).

4. Document medical treatments and agents (s9(4), notes)

• For drug exposures (alkylating agents, topoisomerase II inhibitors, azathioprine, platinum agents, PARP inhibitors), obtain prescribing and chemotherapy records with dates. The Statement requires that treatment commenced at least six months before onset and, if ceased, that onset occurred within 20 years of cessation for the listed agents (s9(4)).

• For ablative radioactive iodine or phosphorus treatments, provide oncological treatment records showing dates of first exposure and that the first exposure occurred at least one year before clinical onset (s9(6)-(7)).

5. Prove antecedent diagnoses where relevant (s9(2)-(3), s9(11)-(14))

• For antecedent haematological disorders, provide diagnosis dates and clinical documentation showing the disorder was present at time of AML onset (s9(2)-(3)). Use the other disease SOPs where relevant per s11.

• For organ or haematopoietic stem cell transplants, procure operative and transplant records; for HIV infection, supply serology and diagnosis dates; for autoimmune diseases, provide clinician diagnoses and relevant clinical notes (s9(11)-(14)).

6. Link the factor to relevant service (s10(1))

• Demonstrate how the factor(s) arose in the course of relevant service. This may require service records, deployment logs, occupational exposure records maintained by Defence, or contemporaneous incident reports. For exposures such as benzene during service tasks, link the task and location to service records and then to the exposure reconstruction. The Statement requires the factor to be related to relevant service; this linkage is a separate element from proving the factor itself.

• For factor 9(18) (inability to obtain appropriate clinical management), ensure the specific limitation is temporally tied to relevant service and that the AML pre-existed or was contracted before/during (but did not arise out of) relevant service as per s10(2).

7. Anticipate cross-application and prepare related SOP evidence (s11)

• Where a factor refers to another injury/disease covered by a separate SOP (for example, MDS), identify that SOP and assemble evidence to meet its requirements. Section 11 directs that factors in that other SOP apply as in force from time to time; prepare accordingly.

8. Use experts where required

• Engage haematologists for disease chronology and causation opinions, occupational hygienists for exposure reconstruction and ppm-year calculations, and radiation dose reconstruction experts using the referenced ARPANSA methodology for radiation factors. Ensure expert reports explicitly address the Statement’s thresholds and the link to relevant service.

9. Present clear analytic narratives in claims

• For adjudicators, present a clear, chronological narrative: (a) date and basis of AML diagnosis; (b) identification and quantification of the applicable s9 factor(s); (c) dates of exposure and calculations showing thresholds are met; (d) linkage of the exposure/factor to relevant service; and (e) explanation of how that linkage satisfies the reasonable hypothesis threshold under the VEA/MRCA processes.

10. Keep contemporaneous records and consider administrative remedies

• Where exposures occurred in service, seek Defence and employment records early. If decision-makers request further information, use internal administrative review pathways under the VEA or MRCA processes. The Statement itself does not set appeals, but timely and precise evidence will aid any merits or judicial review.

Following these steps aligns claim evidence with the Statement’s specified thresholds, definitions and linkage requirement, thereby giving the adjudicating authority the factual basis to find that a reasonable hypothesis connecting AML to relevant service has been raised.